A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

Protocol No
TORAY-950P1V02
Principal Investigator
Ben George
Phase
I
Summary
TRK-950 is an antibody (a protein that helps your immune system find and get rid of foreign cells, in this case your tumor cells). Experiments in the laboratory suggest that it binds with a target on the tumor cell membrane and is thought to inhibit tumor growth. The investigational drug, TRK-950 has not yet been approved for use or proven to be beneficial for the treatment of cancer.
Description
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: